📊 QTTB Key Takeaways
Is Q32 Bio Inc. (QTTB) a Good Investment?
Q32 Bio is a pre-revenue pharmaceutical company burning $6.3M annually in operating cash with minimal revenue generation, indicating it remains in early-stage R&D/clinical development. While the $50.8M cash position provides approximately 8 years of runway and zero debt is a positive, the company generates no offsetting revenue and the fundamentals reveal a value-destructive entity dependent entirely on cash reserves.
Q32 Bio Inc. Key Strengths (QTTB)
- Strong cash position of $50.8M with 8+ year burn runway at current pace
- Zero debt obligation eliminates leverage and refinancing risk
- Excellent liquidity ratios (5.36x current and quick ratio) demonstrate ability to meet obligations
QTTB Stock Risks: Q32 Bio Inc. Investment Risks
- Significant annual cash burn of $6.3M with negative operating cash flow and no revenue generation
- Near-zero revenue (-192K) indicates no meaningful market validation or product commercialization
- Complete financial dependence on existing cash reserves with no path to profitability demonstrated in current data
Key Metrics to Watch
- Operating cash flow trajectory and cash burn rate runway
- Revenue growth and achievement of clinical development milestones
- Changes in insider Form 4 activity and capital raises indicating dilution risk
Q32 Bio Inc. (QTTB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 3,303.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.36x current ratio provides a solid financial cushion.
QTTB Profit Margin, ROE & Profitability Analysis
QTTB vs Healthcare Sector: How Q32 Bio Inc. Compares
How Q32 Bio Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Q32 Bio Inc. Stock Overvalued? QTTB Valuation Analysis 2026
Based on fundamental analysis, Q32 Bio Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Q32 Bio Inc. Balance Sheet: QTTB Debt, Cash & Liquidity
QTTB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Q32 Bio Inc.'s revenue has declined by 40% over the 5-year period, indicating business contraction. The most recent EPS of $-6.58 indicates the company is currently unprofitable.
QTTB Revenue Growth, EPS Growth & YoY Performance
QTTB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | $1.0M | $-1.46 |
| Q2 2024 | N/A | $1.0M | $-1.42 |
| Q1 2024 | N/A | $1.0M | $-6.33 |
| Q3 2023 | N/A | -$28.8M | $0.51 |
| Q2 2023 | $354.0K | -$28.8M | $-0.51 |
| Q1 2023 | $802.0K | -$28.8M | $-0.50 |
| Q3 2022 | $802.0K | -$1.1M | $0.51 |
| Q2 2022 | $802.0K | -$1.1M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Q32 Bio Inc. Dividends, Buybacks & Capital Allocation
QTTB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Q32 Bio Inc. (CIK: 0001661998)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QTTB
What is the AI rating for QTTB?
Q32 Bio Inc. (QTTB) has an AI grade of C with 35% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QTTB's key strengths?
Claude: Strong cash position of $50.8M with 8+ year burn runway at current pace. Zero debt obligation eliminates leverage and refinancing risk.
What are the risks of investing in QTTB?
Claude: Significant annual cash burn of $6.3M with negative operating cash flow and no revenue generation. Near-zero revenue (-192K) indicates no meaningful market validation or product commercialization.
What is QTTB's revenue and growth?
Q32 Bio Inc. reported revenue of $-192.0K.
Does QTTB pay dividends?
Q32 Bio Inc. does not currently pay dividends.
Where can I find QTTB SEC filings?
Official SEC filings for Q32 Bio Inc. (CIK: 0001661998) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QTTB's EPS?
Q32 Bio Inc. has a diluted EPS of $-0.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is QTTB's fundamental grade?
Based on our AI fundamental analysis in May 2026, Q32 Bio Inc. has a C grade with 35% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is QTTB stock overvalued or undervalued?
Valuation metrics for QTTB: ROE of -16.4% (sector avg: 15%), net margin of 3,963.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is QTTB's AI grade for 2026?
Our dual AI analysis gives Q32 Bio Inc. a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is QTTB's free cash flow?
Q32 Bio Inc.'s operating cash flow is $-6.3M, with capital expenditures of $0.0. FCF margin is 3,303.6%.
How does QTTB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 3,963.0% (avg: 12%), ROE -16.4% (avg: 15%), current ratio 5.36 (avg: 2).